Probiotic Improves QOL in Kidney Patients

NEWTOWN SQUARE, Pa.A probiotic dietary supplement (as Renadyl, from Kibow Biotech) has improved quality of life (QOL) in a multisite, pilot-scale study with chronic kidney disease (CKD) Stage III and IV patients kidney patient. Based on results of this trial, Kibow Biotech is actively sponsoring an expanded study of Renadyl administered at higher dosage levels to both predialysis and dialysis patients. These clinical trials, which began in April of 2011, are being conducted at Thomas Jefferson University, Philadelphia, PA; Downstate Medical Center (State University of New York); and at Kings County Hospital in Brooklyn, NY. They are registered at ClinicalTrials.gov, under Kibow Biotech Inc.

Renadyl, originally marketed under the registered name of Kibow® Biotics, is a probiotic dietary supplement which is currently being tested to determine its ability to help reduce the build-up of uremic toxins, and thus help maintain healthy kidney function.  The company said the probiotic microbial strains in Renadyl are "Generally Recognized As Safe" per FDA regulations.